| Literature DB >> 30215272 |
Mark J Stice1, Ty B Dunn1, Melena D Bellin2, Mariya E Skube1, Greg J Beilman1.
Abstract
Total pancreatectomy and islet autotransplantation (TPIAT) is an effective treatment for selected patients with chronic pancreatitis. The portal circulation is the standard infusion site for islet transplant, but marked elevation of portal pressures may prevent complete islet infusion. Herein we report a novel technique of combined site islet autotransplantation using an omental pouch. This technique may be useful when technical limitations prevent complete intraportal transplantation. In four TPIAT recipients with intraoperative issues precluding the complete intraportal infusion of islets, an omental pouch was created to contain the remaining islet mass. Patients were monitored for complications, and islet graft function was assessed using mixed meal tolerance testing and compared with matched controls who received only intraportally transplanted islets. All patients had decreasing insulin requirements as their recovery progressed. At 3 months follow-up there were no significant differences in glycemic control or graft function for the combined site recipients compared with their matched controls who only received an intraportal islet infusion. The omentum has potentially desirable qualities such as accessibility, capacity, and systemic/portal vascularity comparable to the native pancreas. The omental pouch technique may represent a safe and effective alternate site for islet autotransplantation. Further study is needed to confirm these findings.Entities:
Keywords: chronic pancreatitis; extrahepatic islet autotransplantation; islet autotransplantation; omental pouch; total pancreatectomy islet autotransplantation
Mesh:
Year: 2018 PMID: 30215272 PMCID: PMC6180729 DOI: 10.1177/0963689718798627
Source DB: PubMed Journal: Cell Transplant ISSN: 0963-6897 Impact factor: 4.064
Figure 1.Omental pouch creation. (a) Pouch is created by lifting up edges of omentum. The concentrated islet preparation is dripped on to the omentum and affixed using a fibrin sealant hemostatic agent. (b) After islets have been affixed with the hemostatic agent, the pouch is sealed with a running 3-0 Vicryl suture.
Characteristics of Cases and Controls.
| Patient 1 | Controls | Patient 2 | Controls | Patient 3 | Controls | Patient 4 | Controls | |
|---|---|---|---|---|---|---|---|---|
| Sex | Female | F/F | Female | F/F | Male | M/M | Female | F/F |
| TPIAT year | 2017 | 2010/2011 | 2017 | 2011/2011 | 2017 | 2012/2014 | 2017 | 2011/2011 |
| Age (years) | 35 | 38 | 63 | 58 | 49 | 54 | 26 | 22 |
| BMI (kg/m2) | 19.0 | 21.8 | 20.6 | 22.1 | 27.7 | 26.0 | 18.4 | 20.1 |
| Islet yield (IEQ*/kg) | 6,822 | 6,375 | 2,750 | 2,785 | 3,786 | 3,731 | 6,778 | 6,939 |
| Omental islets (%) | 25 | 0 | 36 | 0 | 12 | 0 | 36 | 0 |
Mean values displayed for control patients unless both values are displayed.
TPIAT = Total pancreatectomy islet autotransplantation, BMI = Body mass index, IEQ = Islet equivalent.
* Islet equivalent defined as a pancreatic islet with a diameter of 150 µm.
Figure 2.Comparison of pre-TPIAT and 3-month follow-up glycemic function in omental pouch recipients and their matched controls. Histogram bars represent mean pooled values for all patients in a respective group. Error bars show a single standard deviation. (a) 120 minute glucose results. No significant differences between groups. (b) Peak C-peptide, represented by maximum C-peptide value obtained during MMTT. No significant differences between groups.
Comparison of graft function between cases and controls at 3 months post-operatively.
| Omental pouch | Controls | ||
|---|---|---|---|
| P-value | |||
| MMTT Peak C-peptide (ng/mL) | 2.0 (1.0) | 2.5 (1.1) | 1 |
| Fasting glucose (mg/dL) | 111 (20.5) | 84 (28.4) | .61 |
| MMTT 120 minute glucose (mg/dL) | 145 (29.5) | 115 (19.5) | .31 |
| Hemoglobin A1c (%) | 5.8 (0.33) | 5.9 (0.33) | 1 |
| Basal insulin dose (U/day) | 7.8 (3.6) | 7.4 (4.1) | 1 |
All values are continuous, represented with mean (SD).
MMTT = Mixed meal tolerance test.
Other Described Extrahepatic Sites Used for Islet Autotransplantation.
| Extrahepatic site | Advantages | Disadvantages | Level of investigation | Reference |
|---|---|---|---|---|
| Omentum | Large transplant capacity | Large islet requirement | Nonhuman primate | Yasunami et al.[ |
| Peritoneum | Large transplant capacity | Large islet requirement | Canine | Wahoff et al.[ |
| Gastric submucosa | Rich vascularization | Poorer graft function* | Canine | Yin et al.[ |
| Renal subcapsule | Specific location | Large islet requirement | Nonhuman primate | Rajab et al.[ |
| Intramuscular | Minimally invasive | Poor early vascularization | Porcine | Sterkers et al.[ |
| Bone marrow | Easily accessible | Few clinical studies | Human | Maffi et al.[ |
| Subcutaneous | Minimally invasive | Poor early vascularization | Rat | Sakata et al.[ |
* Compared with intraportal islet autotransplantation, the primary transplant site in current practice.